Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04457531
Other study ID # LIUWEI-V1.1
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date October 26, 2020
Est. completion date December 2023

Study information

Verified date November 2022
Source China Academy of Chinese Medical Sciences
Contact Zhong Wang, Ph.D
Phone 8610-64093207
Email zhonw@sina.vip.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Based on network pharmacology, Liuweiluobi Granule was screened to treat diabetes peripheral neuropathy with deficiency of the spleen and kidney and stasis-heat syndrome.In the preliminary animal experiment, it suggested that this granule had a significant protective effect on the peripheral motor nerves of diabetic peripheral neuropathy and the effect of anti-inflammation, and the prescription did not induce the death of zebrafish at a concentration of 1000 ug/mL, without any obvious toxicity. This study aims to evaluate the efficacy of Liuweiluobi Granule in improving neurotransmission function in patients with diabetic peripheral neuropathy through a pilot, randomized controlled study.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2023
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion criteria 1. Meet the clinical confirmed diagnostic criteria of "diabetic peripheral neuropathy"; 2. Toronto score = 6 points; 3. Meet the Chinese medicine diagnostic criteria of Pi-Shen-Liang-Xu (Deficiency of Pi and Shen) and Yu-Re-Ru-Luo (Collaterals with Stasis and Heat) Zheng (Syndrome) in diabetic peripheral neuropathy; 4. Over 18 years old and under 75 years old, regardless of gender and ethnicity; 5. Have received basic treatment for diabetes controled with stable blood glucose level (fasting blood glucose: <7mmol / L; 2h postprandial blood glucose: <11.1mmol / L; glycated hemoglobin: <8%); 6. Have not taken or stopped taking DPN-related drugs (Mutan granules, Qidan Tongluo granules, pregabalin, duloxetine, etc.) for more than one week; 7. Sign the informed consent form with valid telephone contact information. Exclusion criteria 1. Patients with diabetic ketosis, ketoacidosis or co-infection; 2. Patients with known malignant tumors; 3. Patients with known severe brain diseases, as cerebral infactions with limited activity; 4. Patients with known severe arrhythmias or heart failure over Grade 2 (New York Heart Association), or other known severe heart diseases; 5. Patients with known severe kidney impairment (creatinine =200ummol/L); 6. During the screening or within 24 hours before screening, patients were found to have any of the following laboratory parameter abnormalities (based on local laboratory reference range):-ALT and/or AST level> 2 times the upper limit of normal range (ULN); 7. Patients with spinal cord injury, cervical and lumbar spine lesions (nervous root compression, spinal stenosis, cervical and lumbar degenerative lesions) or sequelae of cerebrovascular disease, neuromuscular junction or muscle disease; 8. Patients with other neuropathy diseases caused by, such as: cerebral infarction, Guillain-Barre syndrome, severe arteriovenous vascular disease (venous embolism, lymphangitis), chronic inflammatory demyelinating polyneuropathy, VitB Deficiency, hypothyroidism, alcoholism, neurotoxicity indused by chemotherapeutic drugs, or metabolic nerve damage caused by renal insufficiency; 9. Patients with severe arteriovenous vascular disease (venous embolism, lymphangitis, etc.); 10. Patients with epilepsy or mental illness; 11. Alcoholics; 12. Patients with a history of psychotropic substance abuse; 13. Patients with allergies or allergies to any drugs in the trial; 14. pregnant women or patients with intention to become pregnant; 15. Participated in other clinical trials in the past 1 month; 16. Patients would not take drug continuously which could affect the evaluation of efficacy; 17. Investigator evaluates as unsuitable to participate in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LiuWeiLuoBi Granule
LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
Other:
Standard medical treatment
Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.

Locations

Country Name City State
China Yuquan Hospital of Tsinghua University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Amino acids, lipid metabolites, vitamins, neurotransmitters and other metabolites Amino acids, lipid metabolites, vitamins, neurotransmitters and other metabolites will be analyzed and tested using targeted metabolic analysis. Baseline, 4 weeks, 8 weeks and 12 weeks
Primary Mean maximal nerve conduction velocity Mean maximal conduction velocity of the common peroneal motor nerve (MCV) and sensory nerve (SCV) 12 weeks
Secondary Michigan Diabetic Peripheral Neuropathy Score (MDNS) Michigan Diabetic Peripheral Neuropathy Score (MDNS) is a 46 point clinical score, with score ranging from 0 to 3 (score of 0, normal; 1, mild to moderate; 2, severe and score of 3, absent). The score is more high means a worse outcome.In MDNS vibration, pain, and light touch are assessed with a 128 Hz tuning fork, a pin, and a 10g filament, respectively. The outcome measures were performed by the investigator at baseline and at the eighth week. Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary Toronto clinical scoring system (TCSS) Toronto clinical scoring system (TCSS) includes three parts: the symptom score of the symptom, the reflection score of the nerve and the evaluation score of the sensory function test. Symptoms include numbness, pain, and needle-like sensation in the lower extremities Feelings of weakness, weakness, instability in walking, and similar symptoms of the upper limbs, such as normal score of 0, 1 point for the presence of corresponding symptoms, a total of 6 points; nerve reflex including ankle reflex and knee reflex, bilateral score, normal score of 0, weakened 1 point, 2 points for disappearance, 8 points in total; sensory function test includes 5 items of pain, temperature, pressure, vibration, and position on the right big toe, 0 points for normal, 1 point for abnormality, 5 points in total With a total score of 19 points. With a score of 0 to 5 do not exist in the DPN, 6 to 8 are mild DPN, 9 to 11 are moderate DPN, 12 to 19 are severe DPN. Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary Quantitative symptoms scales of DPN in Traditional Chinese medicine Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary HbA1c Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary Changes in the level of aldose reductase to 12 weeks
Secondary Fasting blood glucose Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary 2 hrs postprandial blood glucose Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary Total lipids (TC) Lipid level Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary triglycerides (TG) Lipid level Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary high density lipoprotein cholesterol (HDL-C) Lipid level Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary low density lipid Protein cholesterol (LDL-C). Lipid level Baseline, 4 weeks, 8 weeks and 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04638556 - Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
Completed NCT05580705 - Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy N/A
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT00835757 - Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy N/A
Recruiting NCT00553592 - Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes Phase 2
Recruiting NCT05863793 - Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy N/A
Withdrawn NCT05041816 - Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy N/A
Recruiting NCT06074562 - A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Completed NCT02947828 - Polyneuropathy in Diabetes Mellitus Type 2
Completed NCT02056431 - Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy N/A
Completed NCT01681290 - Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes Phase 2
Completed NCT01474772 - Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN) Phase 3
Completed NCT01086150 - Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy Phase 2/Phase 3
Completed NCT03447756 - Titration Study of ABX-1431 Phase 1
Completed NCT04688671 - Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain Phase 2
Completed NCT04984044 - Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms N/A
Completed NCT06130917 - Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN. N/A
Completed NCT01496365 - Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy Phase 2
Completed NCT02332005 - 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study Phase 2/Phase 3